Independence Blue Cross (IBX) continues to make changes to its prescription drug program, which is reviewed and approved by the Pharmacy and Therapeutics Committee, a group that includes practicing physicians and pharmacists.
Effective January 1, 2025, Humira® (adalimumab) will be removed from the IBX Value formulary and will be considered non-formulary. For Select formulary, Humira (adalimumab) will no longer be preferred.
The preferred adalimumab product will be adalimumab-aacf (unbranded Idacio), a lower-cost biosimilar of Humira. We have notified our members of this change by mail.
IBX members will be able to access adalimumab-aacf from their existing pharmacy or from a partnered specialty pharmacy. We will provide additional details both to IBX members and providers on steps to access; stay tuned for more information.
Also, effective January 1, 2025, adalimumab (Humira) will be removed from the Premium formulary and will be considered non-formulary. The preferred adalimumab product for Premium formulary members will be Amjevita® (adalimumab-atto). Providers will receive member-specific notifications identifying which product is preferred for each member, based on the member's formulary.
Learn more
If you have questions about the formulary or the exception process, please contact our pharmacy benefit manager at 1-888-678-7012. For more information about other recent formulary changes, refer to the Pharmacy News section.
To learn more about biosimilars, refer to the IBX Pharmacy and IRA Resource Page, which provides a section with FDA educational material regarding safety, efficacy and potency standards.